Metastatic Hormone and Her-2 Positive Breast Cancer: A Community Approach
| Autor: | Ida Micaily, Lakshmi Kolandra, Shahrzad Abdollahi, Anthony Scarpaci |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Oncology
education.field_of_study medicine.medical_specialty Combination therapy business.industry Population Cancer medicine.disease Metastatic breast cancer chemistry.chemical_compound Regimen Breast cancer chemistry Trastuzumab emtansine Trastuzumab Hormone receptor Internal medicine medicine Community approach education business medicine.drug Hormone |
| Zdroj: | Open Access Journal of Oncology and Medicine. 2 |
| ISSN: | 2638-5945 |
| Popis: | Metastatic hormone-receptor and HER-2 positive (triple-positive) breast cancer provides a treatment dilemma for oncologic clinicians. The current National Comprehensive Cancer Network (NCCN) Guidelines offer a variety of options in the first and second line for metastatic breast cancer. However, a more tailored treatment approach may be needed for the triple-positive metastatic breast cancer population. The aim of this study is to trend the therapeutic treatment selections for patients with metastatic, triple-positive breast cancer at a single, academic-affiliated community practice in the United States. The patient population included individuals with triple-positive, metastatic breast cancer who were treated over the span of six years at this institution. Ultimately, this patient population demonstrated variability across the various treating oncologists choice of therapy in the first, second and fourth line of treatment. The majority of patients (twelve out of fifteen) received combination therapy with trastuzumab in the first line of therapy. In the second line, seven out of eight patients received trastuzumab as part of their treatment regimen. In the third line, all three patients received trastuzumab emtansine as part of their therapy regimen. For patients who were able to survive until the fourth line and beyond, several other treatment options were utilized. Therefore, although metastatic, triple-positive breast cancer represents a subset of patients with vast treatment variability throughout the various lines of therapy, and there is a general lack of consensus on how to best treat this patient population. This study provides an opportunity for more expansive research in the field in order to help elucidate a treatment algorithm for all oncologic practitioners for patients with triple positive, metastatic breast cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|